SNN logo

Smith & Nephew SNATS Inc. (SNN)

$30.97

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SNN

Market cap

$12.99B

EPS

0.56

P/E ratio

19.1

Price to sales

1.84

Dividend yield

2.015%

Beta

0.515635

Price on SNN

Previous close

$31.28

Today's open

$31.49

Day's range

$30.96 - $31.59

52 week range

$26.12 - $37.09

Profile about SNN

CEO

Deepak Nath

Employees

17349

Headquarters

Watford,

Exchange

New York Stock Exchange

Shares outstanding

418708564

Issue type

American Depository Receipt

SNN industries and sectors

Healthcare

Medical Equipment & Supplies

News on SNN

Smith & Nephew SNATS Q3 Earnings Call Highlights

Smith & Nephew SNATS NYSE: SNN lowered its full-year revenue and trading profit outlook after continued weakness in its U.S. knee and hip businesses tempered otherwise stronger third-quarter growth.

news source

MarketBeat • Nov 8, 2026

news preview

Smith & Nephew: Sluggish Growth And Shifting Outlook Now Make It Less Attractive (Rating Downgrade)

Smith & Nephew faces credibility challenges after a profit warning and lowered guidance, despite recent share price gains. SNN cut the full-year underlying revenue growth forecast to 3% and halved expected trading profit growth to around 4%, citing US Orthopaedics weakness. All three business divisions showed year-to-date revenue growth, with Sports Medicine & ENT delivering double-digit gains, but US Hips and Knees remain soft.

news source

Seeking Alpha • Nov 6, 2026

news preview

Smith+Nephew cuts outlook after failed orthopaedics deal talks with J&J

Smith+Nephew cut its full-year revenue and profit forecast on Wednesday as the British medical device maker also confirmed ​that talks about a potential merger with Johnson & Johnson's (JNJ.N), opens new tab orthopaedics ​unit have ended.

news source

Reuters • Nov 4, 2026

news preview

Smith & Nephew plc (SNN) Q3 2026 Sales/Trading Call Transcript

Smith & Nephew plc (SNN) Q3 2026 Sales/Trading Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets

SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.

news source

Zacks Investment Research • Oct 8, 2026

news preview

Smith+Nephew's revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CARTIHEAL Implant will take center stage at this week's International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit in Porto, Portugal from October 8-10.

news source

GlobeNewsWire • Oct 6, 2026

news preview

Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l'innovativo impianto per la riparazione della cartilagine, che sarà presentato all'ICRS Summit in Portogallo.

Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l'innovativo impianto per la riparazione della cartilagine. La tecnologia sarà presentata all'International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, che si terrà a Porto, in Portogallo, dall'8 al 10 ottobre.

news source

GlobeNewsWire • Oct 6, 2026

news preview

Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal

Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización en Europa. El implante CARTIHEAL ocupará un lugar destacado en el Congreso de la Sociedad International de Regeneración de Cartílago & Preservación Articular (ICRS), que se celebrará en Oporto (Portugal) del 8 al 10 de octubre.

news source

GlobeNewsWire • Oct 6, 2026

news preview

Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care

SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.

news source

Zacks Investment Research • Sep 30, 2026

news preview

Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management

The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the EVOS PELVIC Plating System, the next evolution of the EVOS plating platform designed to address the unique challenges of pelvic and acetabular surgery. EVOS PELVIC System is built on the proven principles of the EVOS platform that has become a trusted choice for trauma surgeons worldwide due to its breadth of implant offerings, procedural efficiency and clinically relevant innovation.1-5  EVOS PELVIC System helps surgeons address a broad range of fracture patterns and disruptions in highly complex procedures.

news source

GlobeNewsWire • Sep 23, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Smith & Nephew SNATS Inc.

Open an M1 investment account to buy and sell Smith & Nephew SNATS Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SNN on M1